NEW YORK (GenomeWeb) — Biocept said today that it has signed agreements to sell approximately $2.5 million in stocks and warrants to certain institutional investors.

According to the San Diego-based liquid biopsy firm, it will sell roughly 762,438 shares of its common stock — or pre-funded warrants to purchase common stock — to the investors. The company also plans to issue warrants for the purchase of up to 762,438 shares of its common stock in a concurrent private placement.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Jan
30
Sponsored by
Loop Genomics

This webinar will provide a comparison of several next-generation sequencing (NGS) approaches — including short-read 16S, whole-genome sequencing (WGS), and synthetic long-read sequencing technology — for use in microbiome research studies.

Jan
30
Sponsored by
Loop Genomics

This webinar will provide a comparison of several next-generation sequencing (NGS) approaches — including short-read 16S, whole-genome sequencing (WGS), and synthetic long-read sequencing technology — for use in microbiome research studies.